0000950170-24-012476.txt : 20240207
0000950170-24-012476.hdr.sgml : 20240207
20240207215610
ACCESSION NUMBER: 0000950170-24-012476
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240207
FILED AS OF DATE: 20240207
DATE AS OF CHANGE: 20240207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vida Ventures, LLC
CENTRAL INDEX KEY: 0001724489
ORGANIZATION NAME:
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41947
FILM NUMBER: 24606654
BUSINESS ADDRESS:
STREET 1: 40 BROAD STREET, SUITE 201
CITY: BOSTON
STATE: MA
ZIP: 02109
BUSINESS PHONE: (857) 254-9492
MAIL ADDRESS:
STREET 1: 40 BROAD STREET, SUITE 201
CITY: BOSTON
STATE: MA
ZIP: 02109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kyverna Therapeutics, Inc.
CENTRAL INDEX KEY: 0001994702
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 831365441
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5980 HORTON STREET
STREET 2: SUITE 550
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: 5106268331
MAIL ADDRESS:
STREET 1: 5980 HORTON STREET
STREET 2: SUITE 550
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
3
1
ownership.xml
3
X0206
3
2024-02-07
0
0001994702
Kyverna Therapeutics, Inc.
KYTX
0001724489
Vida Ventures, LLC
40 BROAD STREET, SUITE 201
BOSTON
MA
02109
false
false
true
false
Series A-1 Redeemable Convertible Preferred Stock
Common Stock
967188
D
Series A-2 Redeemable Convertible Preferred Stock
Common Stock
1940388
D
Series B Redeemable Convertible Preferred Stock
Common Stock
1616348
D
The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock has no expiration date and is convertible into the Issuer's Common Stock on a 1-for-4.5511 basis at any time. The number of underlying shares of Common Stock reported in Column 3 reflects an automatic conversion of each outstanding share of Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock into shares of Common Stock at a ratio of 1-for-4.5511 to be effective immediately prior to the closing of the Issuer's initial public offering.
Vida Ventures Advisors, LLC is the investment advisor to the Reporting Person. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by the Reporting Person, but each disclaims beneficial ownership of the shares held by the Reporting Person except to the extent of such person's pecuniary interest therein, if any.
Vida Ventures, LLC, By: /s/ Fred Cohen, Director
2024-02-07